Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients ; day:3 ; month:11 ; year:2018 ; pages:1-12
International journal of clinical oncology ; (3.11.2018), 1-12
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Masuda, Norikazu
Inoue, Kenichi
Nakamura, Rikiya
Rai, Yoshiaki
Mukai, Hirofumi
Ohno, Shinji
Hara, Fumikata
Mori, Yuko
Hashigaki, Satoshi
Muramatsu, Yasuaki
Nagasawa, Takashi
Umeyama, Yoshiko
Huang, Xin
Iwata, Hiroji
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10147-018-1359-3
- URN
-
urn:nbn:de:101:1-2018122219284078744104
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Masuda, Norikazu
- Inoue, Kenichi
- Nakamura, Rikiya
- Rai, Yoshiaki
- Mukai, Hirofumi
- Ohno, Shinji
- Hara, Fumikata
- Mori, Yuko
- Hashigaki, Satoshi
- Muramatsu, Yasuaki
- Nagasawa, Takashi
- Umeyama, Yoshiko
- Huang, Xin
- Iwata, Hiroji
- SpringerLink (Online service)
Ähnliche Objekte (12)
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Rat Models of Hormone Receptor-Positive Breast Cancer
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Rat Models of Hormone Receptor-Positive Breast Cancer
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer
Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
Rat Models of Hormone Receptor-Positive Breast Cancer
The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time
Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients